Outsourced Pharma Capacity Update Videos - Small Molecule

  1. Upperton Pharma Solutions Capacity Update July 2025: Small Molecule Drug Product/Finished Dosage Form 7/29/2025

    Ian Lafferty, CTO, and Josh Moule, Business Development Manager, talk through Upperton’s capabilities, project management approach and provide a virtual tour of their 60,000 sq. ft development and manufacturing facility.

  2. Quotient Sciences Capacity Update July 2025 7/29/2025

    Explore how expedited review pathways can be strategically used to accelerate development while mitigating CMC risks.

  3. PCI Capacity Update July 2025: Small Molecule Drug Product/Finished Dosage Form 7/29/2025

    Dr. Rebecca Coutts highlights PCI’s high potent oral solid dose (OSD) and oral liquid capabilities, focusing on site expertise, specialized infrastructure, and handling of complex molecules.

  4. Your Boutique CDMO Partner Of Choice 7/29/2025

    Lora Wallis and Chris Cuthbertson highlight Douglas CDMO’s strengths in high-potency softgels and liquids and the company's 67 years of expertise and a client-centric approach.

  5. Comprehensive CDMO Services From Clinical To Commercial Supply 7/29/2025

    Bora Pharmaceuticals specializes in formulation development, clinical and commercial manufacturing, and packaging of complex oral solid dose, liquid, semi-solid, and sterile injectable products.

  6. MilliporeSigma Capacity Update July 2025: Small Molecule Drug Substance/API 7/29/2025

    Applications specialist John Stevens shows how MilliporeSigma is using their 35+ years of CDMO experience and expertise to move customers’ small molecules forward to the clinic and beyond to commercialization.

  7. Amorphous Solid Dispersions: Pre-Clinical To Commercial Capabilities 7/29/2025

    ASDs continue to be an attractive option for progressing and commercializing poorly soluble compounds. This talk focuses on capabilities to screen the potential for ASDs in early phase studies as well as their commercial applicability.

  8. Your Integrated Drug Substance Partner 7/29/2025

    With capabilities to support your next small molecule drug substance program from R&D to commercial scale, learn about our integrated facilities, project teams, and available capacity.

  9. Aragen Capacity Update July 2025: Small Molecule Drug Substance/API 7/28/2025

    Explore specialized expertise in solving challenging small molecule formulation problems (poor solubility, bioavailability, complex delivery routes).

  10. Cambrex Capacity Update April 2025: Small Molecule 4/23/2025

    Chief Scientific Officer of Cambrex and President of Snapdragon Chemistry, Matthew Bio, Ph.D., presents the company’s capabilities in the development of peptide therapeutics.